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During the 2019 European Respiratory Society 
(ERS) International Congress in Madrid (Spain), 
the author of the Best Abstract (highest average 
score of abstract reviewers and only those who 
had not applied for a sponsored award) of every 
Assembly was awarded with a prize. Best Abstract 
awardees were invited to write a short summary of 
their congress experience and view on the evolving 
field of research in light of their respective assembly. 
The purpose of this article is to give the readers 
an overview of some of the congress highlights 
and to give a stage to the promising best-abstract 
awardees, as they are the future of the ERS.
Assembly 1: general 
pneumology (Lorna E. Latimer)
The functional capacity and physical activity status 
of people with respiratory diseases plus the effects 
of pulmonary rehabilitation dominated the congress 
agenda. Physical function assessed by 4-m gait 
speed showed prognostic value in COPD [1]. In 
asthma, both increasing habitual physical activity [2] 
and a 3-week intensive pulmonary rehabilitation 
programme [3] increased asthma control.
Evidence that pulmonary rehabilitation improves 
more than just exercise capacity was demonstrated 
across several sessions. Pulmonary rehabilitation 
performed favourably compared to an inhaled long-
acting muscarinic antagonist in COPD for measures 
of symptom burden, health-related quality of 
life (HRQoL) and dyspnoea [4] while cognitive 
function improved in COPD after pulmonary 
rehabilitation [5]. Striking data on >7000 clinical 
patients in England and Wales (UK) demonstrated 
a survival advantage in patients who completed 
pulmonary rehabilitation that was independent of 
disease severity [6].
On the delivery of pulmonary rehabilitation, 
the Clinical Year in Review session highlighted 
that patients with COPD and exercise-induced 
desaturation benefitted from pulmonary 
rehabilitation without the need for supplemental 
oxygen [7] while home-based pulmonary 
rehabilitation may be useful for patients who 
cannot or do not engage in conventional 
outpatient pulmonary rehabilitation [8]. Pulmonary 
telerehabilitation produced similar results to 
conventional pulmonary rehabilitation but in 
both groups, short-term improvements were not 
maintained at 12 months [9]. A post-pulmonary 
rehabilitation maintenance programme showed 
encouraging results (although not a randomised 
trial) with the intervention group maintaining 
exercise capacity and HRQoL for 4 years 
and breathlessness scores for 5 years post-
rehabilitation [10]. However, maintaining physical 
activity levels in COPD patients may be difficult if 
they live in a rainy climate [11].
In COPD experimental exercise physiology, 
transcutaneous electrical nerve stimulation did 
not improve exercise capacity (by disrupting 
muscle afferent feedback) but offered further 
avenues to explore in this fascinating area [12], 
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while eccentric cycling exercise generated lower 
lactic acid accumulation and less dyspnoea than 
concentric cycling [13].
Assembly 2: respiratory 
intensive care (Marieke 
Duiverman)
It is an interesting time for respiratory intensive 
care and home noninvasive ventilation (NIV). A 
new evolving therapy is nasal high-flow therapy 
(nHFT), and studies have been presented on its use 
in the intensive care unit [14], in stable COPD during 
exercise [15] and in interstitial lung disease (ILD) [16]. 
In the coming years, more data will be available 
showing the (added) value of nHFT in chronic care, 
hopefully showing which patient groups benefit. 
Chronic NIV studies mainly focussed on optimisation 
of ventilation techniques, initiation and follow-up 
strategies. Randomised controlled trials (RCTs) 
were presented showing that (telemonitored) home 
initiation of NIV is noninferior to in-hospital initiation 
(in COPD [17], in neuromuscular disease [18] 
and in obesity hypoventilation syndromes [19]), 
although the additional benefit in terms of costs 
seems to depend on the diagnosis, and strategy 
of NIV initiation and follow-up. Furthermore, in 
the poster discussion session “Hot topics in non-
invasive ventilation”, it became evident that real-
life strategies of initial evaluation, selection of 
patients and follow-up are often different from 
those used in RCTs, indicating that there might 
be too little insight into barriers and facilitators of 
implementing evidence-based care. There were 
presentations about measuring patient–ventilator 
asynchrony (PVA), based on flow and airway pressure, 
in a sophisticated automatic way [20]. This strategy 
is attractive as it requires only minimal additional 
measurements and data can be post-processed 
to derive an asynchrony index. However, further 
studies must prove whether this strategy identifies 
all relevant PVAs adequately and whether these PVAs 
are associated with important patient outcomes 
[21]. Overall, to improve care, monitoring chronic 
ventilatory assistance should be practical and lead to 
worthwhile benefits. We are currently at the border of 
a new area of displacing ventilatory assistance more 
and more to the home while improving NIV quality 
by more sophisticated, easy-to-handle, technically 
optimised and worthwhile (tele)monitoring.
Assembly 5: airway 
diseases, asthma and COPD 
(Mahmoud I. Abdel-Aziz)
In 2019, the ERS Congress included several sessions 
in asthma, COPD and airway diseases ranging from 
basic to translational and clinical aspects. Speakers 
in the “It takes two to tango: translating scientific 
findings into clinical applications” symposium 
showed how basic science can be translated into 
clinical application in two major airway diseases: 
asthma and COPD. For example, Marco Contoli 
discussed how functional imaging techniques 
can quantify the contribution of small airways 
as compared to emphysema, and how this could 
predict lung function decline and disease prognosis 
in COPD patients [22, 23]. A hot topic oral session 
was “Beyond type 2 mechanisms in asthma: who are 
the other players?”, during which speakers discussed 
potential biomarkers such as neutrophils, microbiota 
and sex hormones that could direct diagnostic/
therapeutic decisions in non-type 2 asthma.
Numerous original studies were also presented. 
For example, during “The microbiome: novel data 
across respiratory diseases” session, Aogáin 
et al. [24] characterised the airway resistome in 
chronic respiratory diseases using a metagenomics 
approach. They showed that COPD and 
bronchiectasis patients had a higher abundance of 
multiple antibiotic resistance genes as compared to 
severe asthmatics and healthy controls. A study by 
Wedzicha et al. [25] during the “Exacerbations and 
clinical impact of airway diseases” session, showed 
that treatment with tiotropium/olodaterol reduced 
exacerbation rates compared with tiotropium in a 
post hoc analysis of 9942 COPD patients. Moreover, 
during the “Precision meets immunology in 
treatment of airway diseases” session, benralizumab 
was reported by Schwefel et al. [26] to reduce 
the high-affinity immunoglobulin E receptor on 
plasmacytoid dendritic cells in 20 severe asthmatics.
In summary, the 2019 Congress covered 
a broad range of comprehensive topics that 
provide more understanding into the underlying 
pathophysiological mechanisms and treatment 
approaches of airway diseases, asthma and COPD.
Assembly 6: epidemiology 
and environment 
(Gulser Caliskan)
Assembly 6 provides an interdisciplinary approach 
to cover various topics spanning from cutting-edge 
molecular epidemiology of lung function to clinical, 
occupational and environmental epidemiology of 
respiratory disease, in addition, giving emergent 
insights on consumption of tobacco products and 
their control [27].
Khan et al. [28] showed that asthmatic mothers 
who smoked during pregnancy were at greater risk 
of adverse pregnancy outcomes such as premature 
birth, low birth weight and small for gestational age. 
Feliu and coworkers [29, 30] showed that tobacco 
control could result in a lower prevalence of smokers 
and higher quit ratios. Therefore, comprehensive 
tobacco control policies should be considered as they 
are key to reducing the prevalence of smoking and to 
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enhancing tobacco cessation rates in their population. 
They also highlighted that social inequalities in 
heavy smoking necessitates interventions tailored 
to vulnerable groups. Ravara et al. [31] reported 
that prevalence and trends of tobacco use among 
inpatients are similar to those observed in the general 
population. Therefore, a variety of screening strategies 
of tobacco use among inpatients will be crucial in 
the future and a systematic, system-level approach 
in hospitals to quit smoking is recommended. 
During the “From the health effects of tobacco to 
the epidemiology of tobacco/electronic nicotine 
delivery system use” session Caliskan et al. [32] 
showed that the rates of smoking initiation during 
young adolescence (11–15 years) increased steeply 
between 1925 and 1980 in females in Australia. 
After being relatively stable, the rates of smoking 
initiation increased after the 1970s in males. In the 
same period, rates in males (16–20 years) decreased 
steeply, whereas they increased in females. Initiation 
rates among young adults (21–35 years) decreased 
steadily for males, while they started to decrease after 
the 1950s in females [32]. Increased rates of tobacco 
consumption among young women is worrying not 
only for health effects in later life but also because 
tobacco consumption during a susceptible time 
window may impact subsequent generations, possibly 
though epigenetic mechanisms [33]. Tobacco control 
activities during the 90’s are likely to have contributed 
to the decline in smoking prevalence during recent 
decades but their effect on smoking initiation should 
be further investigated. Moreover, a particular focus 
should be given to the effect of tobacco control 
activities during pregnancy.
Assembly 7: paediatrics 
(Sara M. Mensink-Bout)
Life-course studies that showed that lower lung 
function and asthma in early childhood track into 
adulthood and might predict the onset of COPD 
later in life are a hot topic in the field of paediatric 
respiratory diseases [34, 35]. It was emphasised that 
insight into the modifiable risk factors of lower lung 
function and asthma development might provide 
a window of opportunity for preventive strategies. 
Recent research presented at the Congress therefore 
focused on potential risk factors including exposure 
to environmental factors such as air pollution [36] 
and phenolic compounds [37], lifestyle factors 
such as maternal smoking [38] and a selective iron 
supplementation regime during pregnancy [39], and 
growth factors including a “low birth size–slower 
body mass index gain” trajectory [40] and visceral 
adiposity [41] and their relation with respiratory 
morbidity. In addition, sophisticated epidemiological 
approaches to study the combined effect of early life 
exposures and their relation to respiratory morbidity 
were discussed. For example, one study used an 
exposome approach and observed a potential 
adverse effect of several chemicals on lung function 
in children [42]. From a more clinical perspective, 
highlights of past years were the translation of the 
current scientific knowledge into clinical guidelines 
on which symposia were held at the ERS Congress. 
In the symposium on asthma management, it was 
emphasised that children with asthma should not 
be treated with a short-acting β-agonist alone [43]. 
Evidence on the long-term management of children 
with bronchopulmonary dysplasia is scarce; in the 
symposium, it was suggested that these children 
should not be treated with inhaled or systemic 
corticosteroids and that a multidisciplinary 
approach for the long-term management of 
bronchopulmonary dysplasia is needed [44]. 
For chronic cough in children, it was highlighted 
that persistent bacterial bronchitis is a common, 
but often unrecognised, cause of wet cough in 
children that can be treated with antibiotics [45]. 
Furthermore, complex clinical cases were discussed 
with the audience and a panel of experts, including 
the case of a 4-month old girl with pleural effusions 
who appeared to have a chylothorax [46]. Overall, 
the 2019 ERS International Congress provided a 
broad overview of paediatric respiratory diseases, 
ranging from state-of-the-art research to the early 
origins of lung diseases, and to the presentation and 
discussion of evidence-based clinical guidelines on 
the treatment of these diseases.
Assembly 8 – Thoracic 
surgery and Transplantation 
(Alberto Mendoza-Valderrey)
One of the highlights of the thoracic surgery and 
transplantation topics presented during the 2019 
ERS International Congress was the symposium 
on “Lung transplantation (LT) in 2019: where 
are we?”. The importance of ethics in the field of 
lung transplantation was treated by Are Martin 
Holm (Oslo, Norway). Dirk Van Raemdonck 
(Leuven, Belgium) provided recommendations for 
maximising the organ donor pool, emphasising how 
the extracorporeal technology increases the number 
of viable donor lungs [47], besides improving the 
outcome after lung transplantation [48, 49]. In 
line with this, Geert Verleden (Leuven, Belgium) 
concluded that team expertise is an extremely 
important factor to improve long-term outcomes 
following lung transplantation [50].
In the poster discussion session “LT: from basic 
science to clinical outcomes”, Pandolfi et al. [51] 
demonstrated that activated neutrophils induce 
the expression of the profibrotic microRNA miR-
21 in bronchial epithelial cells, suggesting that 
this can be a possible therapeutic target in the 
context of bronchiolitis obliterans syndrome. Vall 
d’Hebron Lung Transplant Unit (Barcelona, Spain) 
shared their findings on a specific gene signature 
in peripheral blood from long-term survivors with 
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normal allograft function after LT [52, 53]. In 
addition, they also presented an integrated mRNA 
and microRNA transcriptomics profiling study that 
suggests that innate immune system may play a 
role in long-term survival after lung transplantation. 
Focusing on clinical studies, Ulvestad et al. [54] 
showed how high-intensity training improves 
physical fitness and health outcomes after lung 
transplantation.
Other sessions in this assembly also focused on 
presenting general thoracic surgery aspects and the 
role of ex vivo lung perfusion, highlighting how this 
technique could improve donor organ quality.
Overall, these sessions highlighted the 
relationship between basic and clinical science in 
order to translate findings into clinical meaningful 
results with the goal of improving survival and 
quality of life of lung transplant recipients.
Assembly 12: interstitial lung 
diseases (Aurélien Justet)
During the 2019 ERS International Congress, several 
major therapeutic breakthroughs were presented. 
Two studies focussed on the efficacy of antifibrotic 
treatments or anti-interleukin (IL)-6 receptor antibody 
in progressive fibrosing ILD and in ILD related to 
systemic sclerosis (SSc). One study retrospectively 
assessed bronchoalveolar lavage (BAL) lymphocytosis 
in fibrotic hypersensitivity pneumonitis to predict 
corticosteroid treatment response.
The INBUILD trial, a double-blind, randomised, 
placebo-controlled study, assessed the efficacy 
and safety of nintedanib in patients with various 
non-idiopathic pulmonary fibrosis (IPF) chronic 
fibrosing ILDs with progressive phenotypes. 
Nintedanib significantly slowed the progression 
of ILD compared to placebo (difference in forced 
vital capacity (FVC) decline 107.0 mL·year−1, 
p<0.001) [55]. Safety profile in this population was 
similar with that observed in IPF population.
In ILD related to SSc, tocilizumab, an anti-IL-6 
receptor antibody, showed clinically relevant lung 
function preservation but failed to improve the 
modified Ronan skin score endpoint. Conversely, the 
SENSCIS trial, a double-blind, randomised, placebo-
controlled study, revealed that nintedanib significantly 
slowed the FVC decline of SSc patients treated with 
prednisone <10 mg·day−1 and/or a stable therapy 
with mycophenolate mofetil or methotrexate [56].
Hypersensitivity pneumonitis is an ILD 
caused by sensitisation to an inhaled antigen. 
Distinguishing fibrotic hypersensitivity pneumonitis 
from nonfibrotic hypersensitivity pneumonitis is 
important, as the extent of histopathological fibrosis 
is associated with survival. One study assessed the 
impact of BAL lymphocytosis and honeycombing 
presence on corticosteroid treatment effect in 91 
patients with fibrotic HP. It revealed that both low 
BAL lymphocyte count and honeycombing predicted 
worse prognosis and the absence of a corticosteroid 
treatment effect [57].
Assembly 13: pulmonary 
vascular diseases 
(Junichi Omura)
In basic research, a study presented by Francois 
Potus provided further insight into the role of 
metabolic syndrome in the development of 
pulmonary hypertension (PH) due to left heart 
disease (LHD). He showed that precapillary PH due 
to diastolic dysfunction (induced by supracoronary 
aortic banding in rats) was exacerbated by a 
metabolic syndrome induced by high-fat diet 
and olanzapine. Mechanistically, he showed that 
pulmonary artery vascular remodelling resulted 
from an increase in circulating IL-6 due to an 
overproduction from both the macrophages and 
fat tissues. Hence, he showed that blocking IL-6 
signalling improved PH-LHD [58].
A promising study by Takayuki Jujo demonstrated 
that gut microbiota was associated with the 
development of PH in SU5416/hypoxia (Su/
Hx) rat model. Furthermore, PH in Su/Hx rats 
was attenuated by antibiotic treatment. There 
is increasing evidence demonstrating the pro-
pathogenic role of inflammation by microbiota in 
cardiovascular disease [59]. Taken together, these 
studies uncover novel mechanisms of the link 
between inflammation and the pathogenesis of PH.
In translational research, there was a pro–
con debate session on current controversies in 
pulmonary artery denervation for PH. This session 
stimulated interest with hot topics, including the 
role of the sympathetic nervous system in PH and 
renal denervation for systemic hypertension.
Finally, the results from ASCO1 study 
(NCT01086540) were presented by Zamanian 
[60]. This clinical trial was designed to assess the 
efficacy and safety of rituximab in SSc associated 
with PH. Although the first endpoint was negative 
in terms of improvement in 6-min walk distance 
(6MWD) at week 24, he showed the significant 
improvement of 6MWD at week 24 (25.5±8.8 m 
rituximab, 0.4±7.4 m placebo; p=0.03) in a pre-
specified secondary analysis that included only 
subjects who were followed until week 48. The 
clinical trial demonstrated that rituximab was a 
safe and potentially effective treatment for PH-SSc.
Assembly 14: clinical 
techniques, imaging and 
endoscopy (Karthi Srikanthan)
As in recent years, the 2019 ERS International 
Congress included a significant number of 
abstracts involving endoscopic techniques. Three 
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of the most interesting abstracts are discussed. 
Firstly, the AIRFLOW-2 trial (randomised, sham-
controlled, double-blind trial of targeted lung 
denervation (TLD) in COPD) presented its 12-month 
outcomes. Similar to its 6-month data, there was a 
significant reduction in the number of patients who 
experienced severe COPD exacerbations in the TLD 
versus sham arm (12% versus 32%, p=0.039). This 
was also the case with respiratory-related serious 
adverse events (15% versus 37%, p=0.042). This 
well-designed trial continues to provide evidence 
that TLD is not only safe but also a signal that 
the denervation technique can be beneficial for 
patients with COPD. A larger pivotal trial is currently 
on-going in the USA and Europe [61]. Secondly, 
the TASMA trial (randomised, controlled trial of 
bronchial thermoplasty (BT) in severe asthma) 
measured airway smooth muscle (ASM) mass in 
endobronchial biopsies before and 6 months after 
BT treatment. Whilst BT has previously been shown 
to reduce ASM mass, this has never been studied 
using a control group. Using a crossover design, the 
TASMA trial demonstrated significant ASM mass 
reduction after BT compared with standard care 
at 6 months (−4.44% versus 0.01%, p=0.02) [62]. 
Lastly, metered CryoSpray is a novel bronchoscopic 
treatment for chronic bronchitis. Using the 
RejuvenAir system (CSA Medical Inc., Lexington, MA, 
USA), liquid nitrogen is aerosolised and applied to 
the bronchial airways to ablate abnormal epithelium 
and promote regeneration of a healthy mucosal 
lining. The aim of the treatment is to improve quality 
of life by targeting mucous overproduction. In a 
multicentre, single-arm study, there was a clinically 
meaningful improvement in St George’s Respiratory 
Questionnaire total score of −7.9±16.8 (95% CI 
−14.2 to −1.6, p=0.008) [63].
Concluding remarks
We hope to reach out to and inspire all clinicians 
and researchers to submit an abstract for the ERS 
International Congress 2020 (Vienna, Austria) as 
this gives them an opportunity to be elected as 
the 2020 Best Abstract awardee of their assembly. 
Abstract submission is open until 13 February 2020. 
Good luck!
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